10. Crossing the Valley of Death – Accelerating the transition from promising targets to clinical candidates Percentage of total cost of success $880M 19% 23% 5% 10% 7% 10% 11% 1% Source: BCG economic model study in Biomedical Industry Advisory Group, 2005; BCG clinical development model, 2007 Target Validation Screen- ing Target ID Optimi-zation Pre- clinical Phase I Phase II Phase III Filing NDA 14% 71% of industry costs 1.0 0.4 2.7 1.5 1.5 2.5 1.5 14.7 2.0 1.6 Avg. time (yr) ARC II 15 - 30 Cost ($M) Basic Research MRF’s ARC Model Proposed ARC Expansion
16. The only non-profit medical research foundation that participates in the entire continuum of drug discovery
Notas del editor
Title slide present while callers are logging/calling in.
Scott
Scott
Russell: Discusses 2-3 particularly interesting discoveries. Scott: Thank you Russell. Other comments?? I am pleased to introduce Dr. Jay Tung, the MRF Vice President for Drug Discovery…